Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Stock Up 13 Percent on Strong Q2 Results

NEW YORK (GenomeWeb News) – Shares in Third Wave Technologies were up 13 percent, or $.31, at $2.66 in mid-afternoon trading today after the company said second-quarter revenues increased while net loss narrowed.
 
As GenomeWeb News reported this morning, Third Wave said revenues increased approximately 17 percent and net losses declined. Clinical molecular diagnostic receipts jumped 18 percent.
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.